Search results: (10000)
News Can Empagliflozin Also Act Against Gout?
Gliflozins, or sodium-glucose cotransporter 2 inhibitors (SGLT2i), are not only effective antidiabetic agents but also exhibit cardio- and renoprotective effects. It now appears that in type 2 diabetics, they may lower serum uric acid levels and help prevent the development of gout. This was suggested by a post hoc analysis of data from the EMPA-REG OUTCOME study in the case of empagliflozin.
News Augmentation Therapy of Bronchiectasis Due to AATD – Case Report
Alpha-1-antitrypsin deficiency (AATD) is a rare cause of bronchiectasis unrelated to cystic fibrosis. The role of augmentation therapy with alpha-1-antitrypsin (AAT) in patients with AATD with bronchiectasis without pulmonary emphysema is still unclear. A case report from authors in Heidelberg presents a patient with bronchiectasis based on AATD, where augmentation therapy reduced the number of exacerbations and improved clinical condition.
News Monocyte Distribution Width as a New Indicator of Sepsis in High-Risk Patients
Most septic patients are first encountered in the emergency department, where sepsis detection is often delayed, partly due to a lack of effective biomarkers. The study presented below evaluated the diagnostic accuracy of monocyte distribution width in peripheral blood alone and in combination with white blood cell count evaluation for early sepsis detection.
News Effect of Prostaglandin Analogues With and Without Preservatives on Meibomian Glands in Glaucoma Patients
Prostaglandin analogues (PGA) have become a standard in the treatment of open-angle glaucoma. However, their long-term use may be associated with eye irritation or damage to the Meibomian glands. The study presented below aimed to determine whether these changes are directly caused by PGAs or the preservatives in the eye drops.
News Current Treatment Options for Multiple Myeloma
Multiple myeloma (MM) accounts for about 10% of all hematologic malignancies. Thanks to advancements in diagnostic methods, it is now understood as a collection of several cytologically distinct plasma cell malignancies. Alongside progress in diagnostics, there has also been rapid development in therapy, significantly improving survival rates for this previously very unfavorable diagnosis, especially in the last 15 years.
News Metformin with Extended Release in the Treatment of Prediabetes
The benefit of metformin in preventing the development of diabetes in people with prediabetes has been demonstrated in clinical studies. However, these studies evaluated immediate-release metformin, not its extended-release form (XR). Therefore, the results of an observational study conducted at Polish and Hungarian centers, which examined the efficacy and safety of metformin XR in patients with prediabetes, are important in this context. It is also necessary to add that in our country, no drug containing this active substance has yet received an approved indication for the therapy of patients with prediabetes.
News Impact of Azacitidine Maintenance Therapy on Survival of Patients with AML in Remission Depending on Initial Chemotherapy
The QUAZAR AML-001 study showed that oral azacitidine maintenance therapy significantly prolongs relapse-free survival (RFS) and overall survival (OS) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (including induction ± consolidation therapy), who are not candidates for hematopoietic stem cell transplantation (HSCT), compared to placebo. In October 2023, results of a subgroup analysis of patients stratified according to the use/non-use of consolidation chemotherapy and the number of consolidation chemotherapy cycles administered before entering the study were published.
News Positive Effect of Pregabalin Not Only on Neuropathic Pain in Patients with Spinal Cord Injury
Spinal cord injury is often accompanied by painful conditions. A study published in the prestigious journal Neurology demonstrated that administering pregabalin to these patients can bring more than just pain relief.
News Trazodone in the Treatment of Depressive Disorder – A Case Study
Presented by MUDr. Sylva Racková, Ph.D.
Psychiatric Clinic, Plzeň
News Tailored Treatment. Who is Teriflunomide Suitable For?
The authors of the recently published study cited below not only focused on the safety and efficacy of teriflunomide in real-world clinical practice but also on the risk factors for its insufficient effectiveness. Who is teriflunomide most suitable for, and when should alternatives be considered?
News Rebound effect after denosumab discontinuation in a patient with lung cancer
The case study of a patient with metastatic lung cancer describes the emergence of vertebral fractures following the discontinuation of denosumab. This antiresorptive treatment was halted prophylactically to reduce the risk of osteonecrosis in connection with a planned dental procedure. Fifteen months after receiving the last dose of denosumab, the patient experienced atraumatic compression fractures of the spine requiring kyphoplasty to alleviate symptoms. Other causes of the fractures were ruled out.
News Updated Recommendations for Treatment of von Willebrand Disease
In 2021, new recommendations for the therapy of von Willebrand disease (vWD) were published, based on a consensus by the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH). The recommendations comprise a total of 12 points and address not only prophylaxis but also gynecological and obstetric issues, for example.
News What Benefits Do Modern Antidiabetics Bring to Patients in Primary Care?
How has the life of patients who now have the opportunity to treat diabetes mellitus in general practice changed? And what do the current prescription conditions for modern antidiabetics bring to their treating physicians? We discuss this and more with diabetologist MUDr. Katarína Nováková.
News Treatment of Glaucoma: Without Preservatives for Everyone?
A comprehensive report by Professor John Thygesen from the University Hospital in Copenhagen analyzes patient groups for whom preservative-free antiglaucoma medications are particularly suitable. In conclusion, he suggests that if there are no price differences, widespread treatment with preservative-free preparations is preferable.
News ESC 2022: Heart Failure with Preserved Ejection Fraction as an Underdiagnosed Problem: How to Increase Its Detection in Everyday Practice?
During this year's European Society of Cardiology Congress (ESC 2022), alarming information was shared, indicating that heart failure with preserved ejection fraction of the left ventricle (HFpEF) is likely underdiagnosed in clinical practice, necessitating improved identification and detection of patients with this condition. One of the symposiums addressed not only the reasons why many patients with HFpEF are misdiagnosed.
News Micronized Diosmin Obtained Reimbursement, Based on Its Therapeutic Interchangeability with MPFF
On January 11, 2022, the State Institute for Drug Control (SÚKL) issued a decision on the determination of the amount and conditions of reimbursement from health insurance for a drug containing micronized diosmin. The reimbursement is valid from March 1, 2022.
News The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease
Current care standards recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) regardless of glycemic compensation in patients with type 2 diabetes (T2DM) and kidney disease, heart failure, or high cardiovascular (CV) risk. A recent study published in the Clinical Journal of the American Society of Nephrology (CJASN) assessed whether long-term use of SGLT2i brings benefits compared to dipeptidyl peptidase-4 inhibitors (DPP4i, i.e., gliptins) in diabetics without documented CV or renal disease using data from a large Israeli database.
News Efficacy and Safety of Levodopa/Entacapone/Carbidopa Combination in the Treatment of Advanced Parkinson's Disease – Prospective ELEGANCE Study
Therapy for advanced Parkinson's disease (PD) with a triple combination of levodopa/entacapone/carbidopa in the form of intestinal gel (LECIG) was first introduced to the Swedish market in 2018. The German team behind the ELEGANCE study aimed to gather available data and analyze the efficacy and safety of this modality in the long-term treatment of PD.
News Prophylaxis EHL products FVIII bring improvements in clinical and pharmacokinetic results
A freshly published real-world clinical practice study from Spain highlights the experience of switching patients with hemophilia A in a prophylaxis setting from standard half-life products to newer products with an extended elimination half-life.